苄氧羰酰基肌氨酸 | 39608-31-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - Cbz-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄氧羰酰基肌氨酸
• 中文别名: Z-肌氨酸；Cbz-肌氨酸；N-(苄氧羰基)肌氨酸；N-苄氧羰基-N-甲基甘氨酸；N-Cbz-甲基甘氨酸
• 英文名称: N-(Benzyloxycarbonyl)sarcosine
• 英文别名: N-Carbobenzoxysarcosin；N-((benzyloxy)carbonyl)-N-methylglycine；glycine, N-methyl-N-[(phenylmethoxy)carbonyl]-；2-[methyl(phenylmethoxycarbonyl)amino]acetic acid
• CAS: 39608-31-6
• 化学式: C₁₁H₁₃NO₄
• mdl: MFCD00021747
• 分子量: 223.229
• InChiKey: CBWFTZNMONHKNZ-UHFFFAOYSA-N

物化性质

• 熔点：
  58-59℃
• 沸点：
  385.6±31.0 °C(Predicted)
• 密度：
  1.26
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 危险类别码：
  R22,R51
• 海关编码：
  2922509090
• 储存条件：
  存储于室温下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-Sar-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H411: Toxic to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-Sar-oh
CAS number: 39608-31-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H13NO4
Molecular weight: 223.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Z-Sar-OH是甘氨酸（HY-Y0966）的衍生物。

反应信息

• 作为反应物：
  描述：

  苄氧羰酰基肌氨酸 在 N,N'-二环己基碳二亚胺 作用下， 生成
  参考文献：
  名称：

  17-氨基酰胺基类固醇抗抑郁药。

  摘要：

  DOI：

  10.1021/jm00282a020
• 作为产物：
  描述：

  ethyl 2-(((benzyloxy)carbonyl)(methyl)amino)acetate 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 苄氧羰酰基肌氨酸
  参考文献：
  名称：

  [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  [FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE

  摘要：

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。

  公开号：

  WO2011159854A1

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist
  申请人：SmithKline Beecham Corporation

  公开号：US05977101A1

  公开（公告）日：1999-11-02

  Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

  Vitronectin受体拮抗剂的化学式为：##STR1##，可用于治疗炎症、癌症和心血管疾病，如动脉粥样硬化和再狭窄，以及骨吸收是因素的疾病，如骨质疏松症。
• Synthesis and antitumor activity of novel C-8 ester derivatives of leinamycin
  作者：Yutaka Kanda、Tadashi Ashizawa、Kenji Kawashima、Shun-ichi Ikeda、Tatsuya Tamaoki

  DOI：10.1016/s0960-894x(02)00949-6

  日期：2003.2

  A novel series of C-8 ester derivatives of leinamycin are described. Condensation of N-substituted amino acids or carboxylic acids containing polyether moiety with leinamycin resulted in the C-8 ester derivatives with good antitumor activity in several experimental models. Among these derivatives, compound 4e, which has five ethylene glycol ether units in the C-8 acyl group, showed potent antitumor

  描述了新型的莱那霉素的C-8酯衍生物系列。N-取代的氨基酸或含有聚醚部分的羧酸与莱那霉素的缩合导致在一些实验模型中具有良好抗肿瘤活性的C-8酯衍生物。在这些衍生物中，化合物4e在C-8酰基中具有五个乙二醇醚单元，显示出对人肿瘤异种移植物的有效抗肿瘤活性。结合二硫杂环戊酮部分的修饰应用于这些C-8酯衍生物，其中一些还显示出良好的抗肿瘤活性。
• Pyrrolidine derivatives
  申请人：——

  公开号：US20020049243A1

  公开（公告）日：2002-04-25

  The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.

  本发明涉及吡咯烷衍生物及其二聚体形式和/或药用可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂，例如锌蛋白酶，特别是锌水解酶，对治疗与血管收缩增加发生相关的疾病状态有效。
• Prodrugs of compounds that inhibit TRPV1 receptor
  申请人：Gomtsyan R. Arthur

  公开号：US20070099954A1

  公开（公告）日：2007-05-03

  Compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

  式（I）的化合物 其中A，R1，R2和R3在规范中定义，并且这些化合物可用作治疗化合物，特别用于治疗与炎症、疼痛、膀胱过度活动、尿失禁以及由TRPV1引起或加重的其他疾病或症状相关的紊乱。

表征谱图